Telomir Pharmaceuticals, Inc.

Analysis for Ticker: TELO

Telomir Pharmaceuticals Inc is a business that claims to be a biotechnology company focused on treating the biological causes of aging and degenerative diseases. The company is walking into a massive financial trap because they just received government permission to start a human clinical trial that they cannot afford to finish. The math is a disaster because the company is carrying the weight of almost seventy-six million shares while trying to fund a trial for seventy-six patients using only a tiny 1$ million cash lifeline from its largest shareholder. Think of it like trying to fly a giant airplane across the ocean with only one gallon of fuel; the plane is simply too heavy and the tank is too empty to reach the other side. The chief executive officer and the founder's family trust have already positioned themselves to take more equity and cash the moment any progress is made, leaving the public shareholders to pay for the entire expensive flight while their own ownership percentage is crushed into smaller and smaller pieces. The roots of this crisis began in 2025 when the company started acting more like a personal bank for its insiders than a research laboratory. During the first nine months of 2025, the company recorded a net loss of 8,4$ million. If you follow the path of that money, you will notice it does not flow into actual scientific discovery. The company spent only 1,1$ million on research and development for its supposed miracle drug, while funneling 7,3$ million into general and administrative expenses. In 05/2025, the board manufactured two million stock options for the part-time chief executive officer, Erez Aminov, and handed him another four hundred thousand fully vested shares worth 840.000$. To fund this, they used an at-the-market offering agreement with Rodman and Renshaw to sell stock directly to the public, offloading 2,6 million shares by September and five hundred fifty thousand more in 10/2025.